Increased endothelial cell expression of a3β1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome

Abstract

The objective of this work was to determine markers of endothelial cell activation in valves from patients with antiphospholipid syndrome (APS) and heart valve involvement, in order to establish a role for endothelial cells in the pathogenesis of the valvular disease.

Sixteen valves from ten patients with APS, obtained from autopsies or removed during valve replacement, were studied. Two groups of valves were used as controls. One group included seven normal valves from patients who died from non-cardiac diseases. The other group of valves were obtained from patients with bacterial endocarditis during autopsies or valve replacement operations.

Immunoperoxidase and immunofluorescence stainings with antibodies to human immunoglobulins, endothelial cells, a₃β₁ integrin, collagen IV, laminin and fibronectin were employed.

Three histopathological patterns were apparent: normal valves, valves with verrucous endocarditis and valves with fibrocalcific changes. In all the valves with verrucous endocarditis the following findings were observed: (1) increased expression of the a₃β₁ integrin on the endothelial cells, (2) increased amount of collagen IV, laminin and fibronectin, (3) proliferation of blood vessels and (4) linear subendothelial deposition of immunoglobulins and complement. The valves with fibrocalcific changes were deformed and showed a thick layer of collagen IV, laminin and fibronectin, yet in two valves the indothelial cells showed an expression of the a₃β₁ integrin. The control valves did not express the integrin and had only a thin subendothelial band of collagen IV.

In valves from patients with APS,¹ markers of endothelial cell activation are upregulated while the inflammatory exudate is scant. There is also a prominent deposition of immunoglobulins in the valves from patients with APS, suggesting a possible association between the deposition of the antibodies and the activation of the endothelial cells in APS.

Keywords

Libman–Sacks endocarditis antiphospholipid syndrome systemic lupus syndrome systemic lupus erythematosus basement membrane anti-cardiolipin antibodies integrins

Get full access to this article

View all access options for this article.

References

Libman E , Sacks B. A hitherto undescribed form of valvular and mural endocarditis . Arch Intern Med 1924; 33: 701–737

Gross L. The cardiac lesion in Libman–Sacks disease with a consideration of its relationship to acute diffuse lupus erythematosus . Am J Pathol 1950; 16: 375–408 .

Shearn MA . The heart in systemic lupus erythematosus: A review . Am Heart J 1959; 58: 452–466 .

Bridgen W , Bywaters EG , Lessof MH et al. The heart in systemic lupus erythematosus . Br Heart J 1960; 22: 1–16 .

Kong TQ , Kellum RE , Haserick JR . Clinical diagnosis of cardiac involvement in systemic lupus erythematosus: A correlation of clinical and autopsy findings in 30 patients . Circulation 1962; 26: 7–11 .

Klinkhof AV , Thompson CR , Reid GD et al. M-mode and two dimensional echocardiographic abnormalities in systemic lupus erythematosus . JAMA 1985; 253: 3273–3277 .

Calve E , Candle-Riera J , Pigrau C et al. Prevalence, morphologic types and evolution of cardiac valvular disease in systemic lupus erythematosus . N Engl J Med 1988; 319: 817–823 .

Straaton KV , Chatham WW , Reveille JD et al. Clinically significant valvular heart disease in systemic lupus erythematosus . Am J Med 1988; 85: 645–650 .

Bulkley BH , Roberts WC . The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 nacropsy patients Am J Med 1975; 58: 243–264 .

10.

Gracia-Torres R , Amigo MC , de la Rosa A et al. Valvular heart disease in primary antiphospholipid syndrome (PAPS): Clinical and morphological findings . Lupus 1996; 5: 56–61 .

11.

Brenner B , Blumenfeld Z , Markiewicz W et al. Cardiac involvement in patients with primary antiphospholipid syndrome . J Am Coll Cardiol 1991; 931–936 .

12.

Cervera R , Khamashta A , Font J et al. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome . Lupus 1991; 1: 43–47 .

13.

Calve E , Ordi J , Barquinero J et al. Valvular heart disease in the primary antiphospholipid syndrome . Ann Intern Med 1992; 116: 293–298 .

14.

Hojnik M , George J , Ziporen L et al. Hert Valve involvement (Liman–Sacks endocarditis) in the antiphospholipid syndrome . Circulation 1996; 93: 1579–1587 .

15.

Ford SE , Charette EJP , Knight J et al. A possible role for antiphospholipid antibodies in acquired valve deformity . J Rheumatol 1990; 17: 1499–1503 .

16.

Asherson Ra , Hughes GRV . The expending spectrum of Libman–Sacks endocarditis: the role of antiphospholipid antibodies . Clin Exp Rheum 1989; 7: 225–228 .

17.

Shapiro RF , Gamble CN , Weisner KB et al. Immunopathogenesis of Libman–Sacks endocarditis . Ann Rheum Dis 1977; 36: 508–516 .

18.

Ziporen L , Goldberg I , Arad M et al. Libman–Sacks endocarditis in the antiphospholipid syndrome: Immunopathologic findings in deformed heart valves . Lupus 1996; 5: 196–205 .

19.

George J , Blank M , Levy Y et al. Differential effect of antib2glycoprotein 1 antibodies on endothelial cells and on the manifestations of experimental APS . Circulation 1998; 97: 900–906 .

20.

Arviexu S , Roussel B , Pouzol P and Colomb MG . Platelet activating properties of murine antibodies to b2 glycoprotein 1 . Thromb Haemost 1993; 70: 336-336 .

21.

George J , Blank M , Gilburd B et al. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human b2 glycoprotein 1 . Int Immunol 1997; 9: 913–921 .

22.

Hynes RO . Integrins: Versatility, modulation, and signalling in cell adhesion . Cell 1992; 69: 11–25 .

23.

Albelda SM . Role of integrins and other cell adhesion molecules in tumor progression and metastasis . Lab Invest 1993; 58: 4–17 .

24.

Springer TA . Adhesion receptors of the immune system . Nature 1990; 346: 425–433 .

25.

Haapasalmi K , Makela M , Oksala O et al. Expression of epithelial adhesion proteins and integrins in chronic inflammation . Am J Pathol 1995; 147: 193–206 .

26.

Tan EM . The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

27.

Morgan CJ . Fibroblast proliferation. In: Cohen Il et al (eds). Wound Healing: Biochemical and Clinical Aspects. Philadelphia: W B Saunders , 1992, pp 63–78.

28.

Belmont HM , Abramson SB , Lie JT . Pathology and pathogenesis of vascular injury in SLE: Interactions of inflammatory cells and activated endothelium . Arthritis Rheum 1996; 39: 9–22 .

29.

Del Papa N , Guidali L , Sala A et al. Endothelial cells as target for antiphospholipid antibodies . Arthritis Rheum 1997; 40: 551–561 .

30.

Alarcon-Segovia D . Clinical manifestations of the anti-phospholipid syndrome . J Rheumatol 1992; 19: 1778–1781 .

31.

Pierangeli SS , Liu XW , Anderson G et al. Thrombogenic properties of murine anticardiolipin antibodies induced by b2 glycoprotein 1 and human IgG antiphospholipid antibodies . Circulation 1996; 94: 1746–1751 .